Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.

Neurological Research and Practice Pub Date : 2022-02-08 DOI:10.1186/s42466-022-00172-1

Maria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, Christos Moschovos, Eleni Bakola, Aikaterini Foska, Konstantinos Melanis, Elisabeth Andreadou, Konstantinos Voumvourakis, Matilda Papathanasiou, Eleni Boutati, Georgios Tsivgoulis

{"title":"Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardy.","authors":"Maria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, Christos Moschovos, Eleni Bakola, Aikaterini Foska, Konstantinos Melanis, Elisabeth Andreadou, Konstantinos Voumvourakis, Matilda Papathanasiou, Eleni Boutati, Georgios Tsivgoulis","doi":"10.1186/s42466-022-00172-1","DOIUrl":null,"url":null,"abstract":"<p><p>This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.</p>","PeriodicalId":19169,"journal":{"name":"Neurological Research and Practice","volume":" ","pages":"6"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8821852/pdf/","citationCount":"9","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42466-022-00172-1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 9

Abstract

This correspondence comments on a published article presenting a case of rhombencephalitis following SARS-CoV-2-vaccination with the mRNA vaccine BNT162b2 (Pfizer/BioNTech). We also present the case of a 47-year-old man who developed Guillain-Barré-syndrome and a fulminant encephalomyelitis 28 days after immunization with Ad26.COV2.S (Janssen/Johnson & Johnson). Based on the presented cases, we underscore the importance of clinical awareness for early recognition of overlapping neuroimmunological syndromes following vaccination against SARS-CoV-2. Additionally, we propose that that role of autoantibodies against angiotensin-converting enzyme 2 (ACE2) and the cell-surface receptor neuropilin-1, which mediate neurological manifestations of SARS-CoV-2, merit further investigation in patients presenting with neurological disorders following vaccination against SARS-CoV-2.

Abstract Image

查看原文本刊更多论文

感染Ad26.COV2后的格林-巴利综合征和暴发性脑脊髓炎。接种疫苗:双重危险。

本通信评论了一篇发表的文章，该文章介绍了使用mRNA疫苗BNT162b2(辉瑞/BioNTech)接种sars - cov -2后出现的一个菱形脑炎病例。我们还报告了一名47岁的男子，他在接种Ad26.COV2后28天出现格林-巴雷氏综合征和暴发性脑脊髓炎。S(杨森/强生)。基于这些病例，我们强调临床意识对于在接种SARS-CoV-2疫苗后早期识别重叠神经免疫综合征的重要性。此外，我们建议针对血管紧张素转换酶2 (ACE2)和细胞表面受体neuropilin-1的自身抗体(介导SARS-CoV-2的神经系统表现)在接种SARS-CoV-2后出现神经系统疾病的患者中的作用值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurological Research and Practice

自引率

0.00%

发文量